Celiac disease is a chronic autoimmune disorder that affects approximately 1% of the global population. It is characterized by an adverse reaction to gluten, a protein found in wheat, barley, and rye, which damages the small intestine and impairs nutrient absorption. The only effective treatment for celiac disease is a strict gluten-free diet, which can be challenging to follow and limit the quality of life for patients. However, several drugs are in development that could potentially offer an alternative or complementary therapy for celiac disease.

Get More Information: https://www.coherentmarketinsights.com/market-insight/celiac-disease-drugs-market-168

One of the most promising drug candidates for celiac disease is larazotide acetate, a peptide that regulates tight junctions in the intestinal epithelium, preventing gluten from passing through the intestinal barrier and triggering an immune response. In a phase 2b clinical trial, larazotide acetate significantly reduced the frequency and severity of gluten-induced symptoms in celiac disease patients who were on a gluten-free diet. A phase 3 clinical trial is currently underway to further evaluate the safety and efficacy of larazotide acetate in celiac disease.

Another drug under investigation for celiac disease is AMG 714, a monoclonal antibody that targets interleukin-15 (IL-15), a cytokine that plays a key role in celiac disease pathogenesis. IL-15 activates immune cells that attack the intestinal lining in response to gluten exposure. In a phase 2 clinical trial, AMG 714 reduced intestinal inflammation and improved symptoms in celiac disease patients who were exposed to gluten. A phase 2b clinical trial is ongoing to assess the safety and efficacy of AMG 714 in a larger cohort of patients.

A third drug candidate for celiac disease is Nexvax2, a peptide vaccine that desensitizes the immune system to gluten. Nexvax2 is designed to stimulate the production of regulatory T cells, which suppress the inflammatory response to gluten. In a phase 1 clinical trial, Nexvax2 was well-tolerated and showed promising immunological results. However, a phase 2 clinical trial was halted due to unexpected adverse events in some patients, and further development of Nexvax2 is currently on hold.

In conclusion, while a gluten-free diet remains the gold standard treatment for celiac disease, the development of new drugs offers hope for patients who struggle with adherence to a restrictive diet or experience persistent symptoms despite gluten avoidance. Larazotide acetate, AMG 714, and Nexvax2 are among the most promising drug candidates for celiac disease, and ongoing clinical trials will determine their safety and efficacy for potential use in the future.